Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms

HIGHLIGHTS

• who: Zachary Ladd from the University of Missouri, United States have published the article: Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms, in the Journal: (JOURNAL)
• what: The authors demonstrate Frontiers in Cardiovascular Medicine that inhibition of eATP release, likely from Panx 1 channels, by spironolactone downregulates the intercellular communication leading to significantly reduced macrophage and SMC activation. This study shows that spironolactone can be effectively used for the significant mitigation of vascular inflammation and remodeling to inhibit the AAA progression.
• future: Studies with pre-clinical porcine models are required to enable . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.